Showing results (71-80 of 429) with videos related to
Sort By:
Pageof 43
CNS Drug Reviews|December 14, 2004
Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacologyMarilyn A Davies, Douglas J Sheffler, Bryan L RothNeuropharmacology|July 22, 2008
Insights into the regulation of 5-HT2A serotonin receptors by scaffolding proteins and kinasesJohn A Allen, Prem N Yadav, Bryan L RothJournal of Neurochemistry|November 19, 2021
Molecular insights into psychedelic drug actionSamuel T Slocum, Jeffrey F DiBerto, Bryan L RothCell Reports|August 17, 2022
Molecular insights into the regulation of constitutive activity by RNA editing of 5HT2C serotonin receptorsRyan H Gumpper, Jonathan F Fay, Bryan L RothAddiction Neuroscience|August 1, 2024
Xylazine is an agonist at kappa opioid receptors and exhibits sex-specific responses to opioid antagonismMadigan L Bedard, Xi-Ping Huang, Jackson G Murray, et al.Proceedings of the National Academy of Sciences of the United States of America|December 24, 2008
Structural basis for antagonism of human interleukin 18 by poxvirus interleukin 18-binding proteinBrian Krumm, Xiangzhi Meng, Yongchao Li, et al.Plos Pathogens|August 29, 2012
A unique bivalent binding and inhibition mechanism by the yatapoxvirus interleukin 18 binding proteinBrian Krumm, Xiangzhi Meng, Zhixin Wang, et al.Bioorganic & Medicinal Chemistry Letters|January 24, 2007
Further studies on the binding of N1-substituted tryptamines at h5-HT6 receptorsAbner Nyandege, Renata Kolanos, Bryan L Roth, et al.Bioinformatics (Oxford, England)|December 31, 2013
HTS navigator: freely accessible cheminformatics software for analyzing high-throughput screening dataDenis Fourches, Maria F Sassano, Bryan L Roth, et al.Pharmacological Reviews|September 26, 2019
Harnessing Ion-Binding Sites for GPCR PharmacologyBarbara Zarzycka, Saheem A Zaidi, Bryan L Roth, et al.Pageof 43